New antibody shows strong potential against pancreatic cancer
SIWA318H specifically targets and removes senescent cells in pancreatic tumors, slowing their growth PHOENIX, AZ — Oct. 12, 2023 — Scientists at the Translational Genomics Research Institute (TGen), part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product (AGE)-targeting antibody, in the fight against pancreatic cancer. The results appear in Scientific Reports, a Nature publication. Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), has long been known for its aggressive nature and resistance to current treatment options. SIWA318H’s ability to selectively target senescent cells represents a new approach to treating the disease. Senescent cells within the tumor microenvironment have been identified as major contributors to tumor development, growth and therapy resistance. SIWA318H, an antibody specifically designed to target AGEs, offers…